PL442478A1 - Kompozycja szczepionki do zastosowania w profilaktyce chorób zakaźnych - Google Patents

Kompozycja szczepionki do zastosowania w profilaktyce chorób zakaźnych

Info

Publication number
PL442478A1
PL442478A1 PL442478A PL44247822A PL442478A1 PL 442478 A1 PL442478 A1 PL 442478A1 PL 442478 A PL442478 A PL 442478A PL 44247822 A PL44247822 A PL 44247822A PL 442478 A1 PL442478 A1 PL 442478A1
Authority
PL
Poland
Prior art keywords
vaccine composition
prevention
infectious diseases
antigen
cov
Prior art date
Application number
PL442478A
Other languages
English (en)
Inventor
Monika Staniszewska
Joanna Baran
Łukasz Kuryk
Mariangela GAROFALO
Katarzyna Wanda Pancer
Anna Mazurkiewicz-Pisarek
Alina Mazurkiewicz
Diana MIKIEWICZ
Tomasz CIACH
Ewa Augustynowicz-Kopeć
Sylwia Brzezińska
Agnieszka Iwańska
Original Assignee
Politechnika Warszawska
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Politechnika Warszawska filed Critical Politechnika Warszawska
Priority to PL442478A priority Critical patent/PL442478A1/pl
Publication of PL442478A1 publication Critical patent/PL442478A1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Pulmonology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Przedmiotem zgłoszenia jest kompozycja szczepionki zawierająca antygen i adiuwant, przy czym antygen stanowi białko kolca SARS CoV-2 wybrane z grupy obejmującej rekombinowane białko rRBD o sekwencji SEQ ID NO 1 i lentiwirusa pseudotypowanego białkami kolca SARS-CoV-2.
PL442478A 2022-10-10 2022-10-10 Kompozycja szczepionki do zastosowania w profilaktyce chorób zakaźnych PL442478A1 (pl)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PL442478A PL442478A1 (pl) 2022-10-10 2022-10-10 Kompozycja szczepionki do zastosowania w profilaktyce chorób zakaźnych

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL442478A PL442478A1 (pl) 2022-10-10 2022-10-10 Kompozycja szczepionki do zastosowania w profilaktyce chorób zakaźnych

Publications (1)

Publication Number Publication Date
PL442478A1 true PL442478A1 (pl) 2024-04-15

Family

ID=90716777

Family Applications (1)

Application Number Title Priority Date Filing Date
PL442478A PL442478A1 (pl) 2022-10-10 2022-10-10 Kompozycja szczepionki do zastosowania w profilaktyce chorób zakaźnych

Country Status (1)

Country Link
PL (1) PL442478A1 (pl)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021178623A1 (en) * 2020-03-05 2021-09-10 New York Blood Center, Inc. Immunogenic compositions against severe acute respiratory syndrome coronavirus 2
WO2022013405A1 (en) * 2020-07-15 2022-01-20 Institut Pasteur Sars-cov-2 immunogenic compositions, vaccines, and methods

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021178623A1 (en) * 2020-03-05 2021-09-10 New York Blood Center, Inc. Immunogenic compositions against severe acute respiratory syndrome coronavirus 2
WO2022013405A1 (en) * 2020-07-15 2022-01-20 Institut Pasteur Sars-cov-2 immunogenic compositions, vaccines, and methods

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CH.O. BARNES ET AL.:: "Cell. 2020 Aug 20; 182(4): 828–842.e16", STRUCTURES OF HUMAN ANTIBODIES BOUND TO SARS-COV-2 SPIKE REVEAL COMMON EPITOPES AND RECURRENT FEATURES OF ANTIBODIES *
D. F. ROBBIANI ET AL.:: "Nature. 2020 August ; 584(7821): 437-442", CONVERGENT ANTIBODY RESPONSES TO SARS-COV-2 IN CONVALESCENT INDIVIDUALS *

Similar Documents

Publication Publication Date Title
DK1278534T3 (da) Fremgangsmåder og sammensætninger til svækkelse af multiplikationen af HIV-1
ATE286067T1 (de) Hcv hüllproteine partikel : verwendung für therapeutische impfung
WO2004006952A3 (en) Therapeutic tuberculosis vaccines
BRPI0208183B8 (pt) peptídeo antígeno de câncer modificado por wt1 e vacinas para câncer
RU2010111758A (ru) Иммуногенные композиции и способы
DE68927348D1 (de) Künstlicher impfstoff gegen aids-virus
DE602005020165D1 (de) Verfahren zur herstellung von l-arginin, l-ornithin oder l-citrullin
ATE496630T1 (de) Immunologische zusammensetzung und impfstoffe, die einen auf n-formyl-methionyl peptide bestehenden adjuvans enthalten
CO2022013121A2 (es) Vacuna 2019-ncov (sars-cov-2)
WO2023094713A3 (en) Coronavirus vaccine
WO2021000968A3 (zh) 一种用于预防SARS-CoV-2感染的腺病毒载体疫苗
ES2127294T3 (es) Vacunas del virus de la inmunodeficiencia anti-felino (fiv).
ATE495247T1 (de) Chromoprotein und fluoroproteine
WO2023147092A3 (en) Coronavirus vaccine
ATE482272T1 (de) Zytokinproteinfamilie
PL442478A1 (pl) Kompozycja szczepionki do zastosowania w profilaktyce chorób zakaźnych
AU6683400A (en) Vaccine against lentiviral infections, such as the feline immune deficiency virus of the cat
ATE435034T1 (de) Expression und charakterisierung eines hiv-1 hüllproteins, das mit einer breitreaktiven neutralisierenden antikörperantwort assoziiert ist.
DE60332425D1 (de) 5t4-antigen-peptidepitope der mhc klasse ii
ATE493146T1 (de) Igf-1 als impfstoffhilfsmittel für katzen, insbesondere gegen feline retroviren
WO2022047176A3 (en) Single-chain coronavirus viral membrane protein complexes
DE3776034D1 (de) Vakzine.
CN1226046C (zh) 来自逆转录病毒调节蛋白的无毒免疫原、抗体、其制备方法和含有它们的药物组合物
DK0811067T3 (da) Equin arteritisviruspeptider, antistoffer og deres anvendelse i en diagnostisk test
US11413345B2 (en) Synthetic hemagglutinin as universal vaccine against infection by type B influenza viruses (IBV)